Okada M, et al. - Experts gauged the treatment outcomes, hearing outcomes, and adverse effects of rituximab (RTX) for intractable otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV). Findings suggested the safety and efficacy of RTX for intractable OMAAV patients who have a poor response to GC and IVCY. In the non-RTX group, a significantly better hearing level at remission was seen, whereas, between the groups, hearing gain did not differ significantly.